The companies said they will train, model, and expand insights continuously using machine learning and artificial intelligence, with the goal of enabling early identification of people at high risk for PTSD and other behavioral health conditions based on their biomarkers.
Researchers used data collected by the UK-based Breast Cancer Association Consortium over the last 15 years employing new analytical methods to identify variants that can have different effects for different types of cancer.
The results indicate that while the DNA of individuals with autism may harbor different alterations, the activity of these genes is similar in people with the disorder, and differs from that of the same genes in the brains of people without autism.
According to PrecisionLife, the 59 drug candidates could be studied in future drug trials and repurposing projects—and also hold potential as high-risk biomarkers for COVID-19.
Sponsor: IlluminaIn this inaugural Clinical OMICs Keynote webinar, we are proud to host two renowned leaders in the field of genomic medicine, Drs Stephen Kingsmore and Robert Green, who will discuss their pioneering work in the field of newborn genome sequencing and analysis.
The study showed that the hormone vasopressin was present at much lower levels in the CSF of 0–3-month-old babies who were later diagnosed with ASD than it was in CSF samples from infants who weren’t subsequently diagnosed with ASD.
The researchers found that rare variation in the gene TET2 nearly doubled the risk of developing diseases like Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Issues related to patient sample collection, processing, and analyses have long been important factors in handling the response to emerging infectious diseases.
As the market for immunotherapies grows, doctors’ interest in diagnostics to guide more precise treatment increases.
The detection of CTCs with the Genesis System has several potential clinical research applications in cancer. This technology could guide upfront treatment decisions, predict which tumors will metastasize, and identify therapeutic response early in the treatment cycle, thereby allowing decisions about whether to stop or continue their course of therapy.